Liraglutide treatment in overweight and obese patients with type 1 diabetes: A 26‐week randomized controlled trial; mechanisms of weight loss
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Aim: To investigate the effects of liraglutide treatment on glycaemic control and adipose tissue metabolism in overweight and obese people with type 1 diabetes (T1DM). Research design and methods: A total of 84 adult overweight and obese patients with T1DM, with no detectable C‐peptide, were randomized (1:1) to either placebo or 1.8 mg/d liraglutide for 6 months. Blood samples were collected at 0, 12 and 26 weeks. Subcutaneous adipose tissue biopsies, a high‐calorie high‐fat meal challenge test, continuous glucose monitoring, dual‐energy X‐ray absorptiometry and MRI were performed before and at the end of treatment. Results: In all, 37 and 27 patients who received liraglutide and placebo, respectively, completed the study. Glycated haemoglobin fell by 0.41 ± 0.18% (4.5±1.4 mmol/mol) from baseline after liraglutide treatment ( P = 0.001), and by 0.29 ± 0.19% (3.1±2.0 mmol/mol) compared to placebo ( P = 0.1). There was no increase in hypoglycaemia, while the time spent in normal glycaemia increased ( P = 0.015) and time spent in hyperglycaemia decreased ( P = 0.019). Body weight fell significantly in the liraglutide group, mostly in the form of fat mass loss (including visceral fat), with no change in lean mass. Systolic blood pressure (SBP) also fell after liraglutide treatment. Liraglutide also caused a significant increase in the expression of adipose tissue triglyceride lipase, carnitine palmitoyl transferase‐1, peroxisome proliferator‐activated receptor (PPAR)α, PPARδ, uncoupling protein‐2 and type 2 iodothyronine deiodinase in the adipose tissue. Conclusions: Liraglutide improves glycaemia, reduces adiposity and SBP. Liraglutide also stimulates mechanisms involved with an increase in lipid oxidation and thermogenesis, while conserving lean body mass.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A general introduction to the biochemistry of mitochondrial fatty acid β‐oxidation
Houten, S. M., & Wanders, R. J. A. (2010) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-010-9061-2 · Cited by 1,020
Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects
BONNEFONT, J. (2004) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2004.06.004 · Cited by 637 · cited 1×
“ATGL increases lipolysis of stored triglycerides, while CPT-1 increases the transport of lipolysis-induced FFAs across the mitochondrial membrane into the mitochondrial matrix for β-oxidation.(14,15) It is relevant that, in spite of the increase in ATGL, there was a decrease in plasma FFA concentration.”
BackgroundGLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK
Beiroa, D., Imbernon, M., Gallego, R., Senra, A., Herranz, D., Villarroya, F., Serrano, M., Fernø, J., Salvador, J., Escalada, J., et al. (2014) · Diabetes · doi:10.2337/db14-0302 · Cited by 602 · cited 4×
“Similarly, centrally infused liraglutide in mice activates GLP-1 receptor in the ventromedial nucleus of the hypothalamus, triggering AMPK inhibition and leading to sympathetic-induced BAT thermogenesis and browning of white adipose tissue.(11) It is of interest that, in the present study, the adipose tissue expressio…”
BackgroundResultInfluentialPetrie, J. R., Chaturvedi, N., Ford, I., Brouwers, M. C. G. J., Greenlaw, N., Tillin, T., Hramiak, I., Hughes, A. D., Jenkins, A. J., Klein, B. E. K., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30194-8 · Cited by 357 · cited 1×
“However, data from the REMOVAL study do not support use of metformin to improve glycaemic control.(20) Similarly, a recent meta-analysis found only modest change in HbA1c after addition of metformin to T1DM therapy.”
ResultSelf-citationHeymsfield, S. B., Gonzalez, M. C. C., Shen, W., Redman, L., & Thomas, D. (2014) · Obesity Reviews · doi:10.1111/obr.12143 · Cited by 350
Mathieu, C., Zinman, B., Hemmingsson, J. U., Woo, V., Colman, P., Christiansen, E., Linder, M., Bode, B., & for the ADJUNCT ONE Investigators (2016) · Diabetes Care · doi:10.2337/dc16-0691 · Cited by 347
Ahrén, B., Hirsch, I. B., Pieber, T. R., Mathieu, C., Gómez-Peralta, F., Hansen, T. K., Philotheou, A., Birch, S., Christiansen, E., Jensen, T. J., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0690 · Cited by 262
Vendrell, J., El Bekay, R., Peral, B., García-Fuentes, E., Megia, A., Macias-Gonzalez, M., Real, J. F., Jimenez-Gomez, Y., Escoté, X., Pachón, G., et al. (2011) · Endocrinology · doi:10.1210/en.2011-1070 · Cited by 173 · cited 1×
“proportion to the co-existent insulin resistance.(13) However, there are no previous data on the loss of body fat in association with the preservation of lean body mass following liraglutide in patients with T1DM.”
BackgroundSantilli, F., Simeone, P. G., Guagnano, M. T., Leo, M., Maccarone, M. T., Di Castelnuovo, A., Sborgia, C., Bonadonna, R. C., Angelucci, E., Federico, V., et al. (2017) · Diabetes Care · doi:10.2337/dc17-0589 · Cited by 114 · cited 2×
“There was also a significant reduction in SBP, consistent with our original observation with exenatide(9) and further confirmatory and mechanistic observations with GLP-1 receptor agonists.(10,11) It is of interest that metformin was also proposed as an adjunct therapy in T1DM.”
BackgroundResultKuhadiya, N. D., Dhindsa, S., Ghanim, H., Mehta, A., Makdissi, A., Batra, M., Sandhu, S., Hejna, J., Green, K., Bellini, N., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1136 · Cited by 101
Self-citationMeng, H., Zhang, A., Liang, Y., Hao, J., Zhang, X., & Lu, J. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2983 · Cited by 56 · cited 1×
“Similarly, a recent meta-analysis found only modest change in HbA1c after addition of metformin to T1DM therapy.(21) However, in both studies, 1750 GHANIM ET AL.”
Result
Research works printed but not linked: 14
- 10.1530/EJE-11-0330 · DOI · Paper page
- 10.1016/j.clinthera.2009.11.034 · DOI
- 10.1111/jch.13447 · DOI
- 10.1111/dom.12944 · DOI
- 10.1016/j.ejrad.2006.01.012 · DOI
- 10.1530/JOE-18-0374 · DOI · Paper page
- 10.1016/j.bbagen.2012.08.019 · DOI · Paper page
- 10.1074/jbc.M112.374041 · DOI · Paper page
- 10.2337/db07-1318 · DOI · Paper page
- 10.1371/journal.pone.0191365 · DOI
- 10.1161/CIRCULATIONAHA.118.035525 · DOI · Paper page
- 10.1002/cne.23282 · DOI · Paper page
- 10.2337/db11-1556 · DOI · Paper page
- 10.1016/j.cmet.2016.08.003 · DOI · Paper page
Cited by
Karakasis, P., Patoulias, D., Fragakis, N., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2024.156113 · Cited by 242
Vosoughi, K., Atieh, J., Khanna, L., Khoshbin, K., Prokop, L. J., Davitkov, P., Murad, M. H., & Camilleri, M. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.101213 · Cited by 97
Park, J., Ntelis, S., Yunasan, E., Downton, K. D., Yip, T. C.-F., Munir, K. M., & Haq, N. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad471 · Cited by 69
Vosoughi, K., Salman Roghani, R., & Camilleri, M. (2022) · Obesity Medicine · doi:10.1016/j.obmed.2022.100456 · Cited by 65
Beavers, K. M., Cortes, T. M., Foy, C. M., Dinkla, L., Reyes San Martin, F., Ard, J. D., Serra, M. C., & Beavers, D. P. (2025) · Obesity · doi:10.1002/oby.24172 · Cited by 41
Metadata
- Authors
- Ghanim, H., Batra, M., Green, K., Abuaysheh, S., Hejna, J., Makdissi, A., Borowski, R., Kuhadiya, N. D., Chaudhuri, A., & Dandona, P.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2020-07-08
- Volume
- 22
- Issue
- 10
- Pages
- 1742-1752
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W3028010767
- Cited by
- 86
- References
- 11
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.